Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (m...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter F. Marmorino
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors F. Marmorino1, C. Cremolini1, F. Loupakis1, C. Antoniotti1, C. Barbara2, F. Dargenio3, E. Miraglio4, G. Masi5, L. Salvatore1, M. Schirripa1, B. Borelli6, L. Marcucci7, L. Antonuzzo8, S. Chiara9, C. Banzi10, D. Amoroso11, A. Bonetti12, A. Martignetti13, M. Paris14, L. Boni15, D. Tomcikova16, A. Falcone17
  • 1Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, /
  • 2U.O. Oncologia Medica, Ospedale Civile Livorno, Livorno, Italy, /
  • 3Oncologia Medica Piombino, Piombino, Italy, /
  • 4U.O. Oncologia Medica, Azienda Sanitaria Ospedaliera S. Croce e Carle, Cuneo, Italy, /
  • 5U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, /
  • 6Oncologia Medica 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, /
  • 7U.O. Oncologia Medica, Azienda USL-5 Istituto Toscano Tumori, Pontedera, Italy, /
  • 8Medical Oncology, Careggi University Hospital, Firenze, Italy, /
  • 9U.O. Oncologia Medica 2 IRCCS Azienda Ospedaliera Universitaria “San Martino” - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, /
  • 10Arcispedale Santa Maria Nuova, IRCCS Reggio Emilia, Reggio Emilia, Italy, /
  • 11Ospedale Versilia, Viareggio, Italy, /
  • 12U.O. Oncologia, Ospedale Mater Salutis, Legnago, Italy, /
  • 13Unita Operativa Di Oncologia Medica, Siena, Italy, /
  • 14S.O.C. Oncologia - Ospedale degli Infermi, Biella, Italy, /
  • 15Clinical Trials Coordinating Center, Istituto Toscano Tumori, Firenze, Italy, /
  • 16Istituto Toscano Tumori, Florence, Italy, /
  • 17Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, /

Abstract

Different antiangiogenic agents are available as 2nd-line options for mCRC patients (pts). Up today, no clinical or molecular predictors of benefit have been identified. In preclinical and clinical studies LDH levels are a marker of angiogenesis activity. High LDH levels are associated with worse prognosis in never pretreated mCRC pts and a potential positive predictive impact with regard to the efficacy of 1st-line bev has been hypothesized in retrospective analyses. The aim of this analysis was to assess the prognostic and predictive impact of LDH levels measured before the beginning of the 2nd-line treatment in pts randomized to continue or not bev after progression to 1st-line CT plus bev in the BEBYP study.